ASP Isotopes Inc.

As of June 30, 2026, ASP Isotopes, Inc. carries a market capitalization of 709.31M, placing it among publicly traded companies globally. Its enterprise value stands at 730.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ASP Isotopes, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, ASP Isotopes, Inc. has 130.15M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 21.49, and the price-to-book ratio stands at 3.06.

These figures are as of June 30, 2026. The EV/Sales ratio of 27.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 730.97M versus a market cap of 709.31M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ASP Isotopes, Inc. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 98.09, indicating elevated leverage, while an interest coverage ratio of -23.94 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. posted a negative return on equity (ROE) of -91.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.30, reflecting losses generated across the asset base. The company generates approximately 113,824.23 in revenue per employee across its workforce of 237.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 19.59 indicates how many times ASP Isotopes, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. recorded 113,335.59 in income tax expense. The company reported a pretax loss of -119.74M and -115.58M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, ASP Isotopes, Inc.'s stock has declined approximately 75.74% over the past 52 weeks. The 50-day moving average sits at 2.81, while the 200-day moving average is 4.30.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. generated 27.00M in revenue and converted that into -115.58M in net income, yielding earnings per share of -1.13. EBITDA reached -81.91M, while operating income came in at -84.34M.

As of June 30, 2026, ASP Isotopes, Inc. holds 223.11M in cash and equivalents against 235.93M in total debt, resulting in a net debt position of 38.10M. Total book value stands at 231.69M, with working capital of 176.71M providing operational flexibility.

ASP Isotopes, Inc. produced -59.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -13.81M in capital expenditures, free cash flow totaled -73.15M - equivalent to -0.69 per share.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. posted a gross margin of 18.32, reflecting its pricing power and cost economics. The operating margin of -312.31 and net profit margin of -428.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -44.61, meaning ASP Isotopes, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ASP Isotopes, Inc. has an Altman Z-Score of 0.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.